Two research studies to benefit patients

An invitation to participate in two research study surveys. Please consider participating in the surveys detailed below: Curtin University research study Please complete a brief (5mins) online questionnaire which is part of the following research study: Knowledge, attitudes and practice of oncologists in promoting physical activity to cancer survivors Please click … Read More

February 15, 2017

Work after Cancer

A new web resource to support return to work after cancer has been established by the team at the Flinders Centre for Innovation in Cancer, supported by Cancer Australia. The online resource  is aimed at supporting work during and after cancer diagnosis. The web resource is a result of a … Read More

February 15, 2017

Significant highlights for the AGITG

CommNETS abstract presented as oral presentation at ASCO GI. With great pleasure we inform you that our abstract: Development of follow up recommendations for completely resected gastroenteropancreatic neuroendocrine tumours (GEP-NETS): Practice Survey of Commonwealth Neuroendocrine Tumour Collaboration (CommNETS) in conjunction with North American Neuroendocrine Tumour Society (NANETS)- was given an oral presentation … Read More

February 15, 2017

AGITG Trial News

The AGITG currently has eight studies open to recruitment and ten studies in follow up. The table below details the trials that are currently accruing patients. Recruited Target ACTICCA-1- Gallbladder carcinoma 0 50 ALT-GIST- GI Stromal Tumour 57 240 ASCOLT – Colorectal cancer 92 300 CONTROL NETs – NeuroEndocrine Tumour 42 73 INTERAACT – Anal cancer … Read More

February 15, 2017

Engage Forums featured at Conference

This year the Survivorship Conference was again held in Adelaide in February. The conference brings together a diverse group of clinicians, researchers, policy makers and consumers from around Australia and beyond to make a lasting impact on the lives of those affected by cancer. The theme this year was “Cancer … Read More

February 14, 2017

First patient randomised for InterAACT

The first Australian patient has been randomised to the InterAACT study. This patient was from Austin Hospital (PI: A/Prof Niall Tebbutt) and was randomised 4th January 2017. More patients are needed so referrals are welcome. InterAACT is an international, multicentre trial aiming to establish which chemotherapy regimen is more effective … Read More

February 14, 2017

ALaCaRT recognised by ASCO

The ALaCaRT rectal surgery trial was recently selected by the American Society of Clinical Oncology for inclusion in Clinical Cancer Advances 2017, the society’s annual review of progress against cancer and emerging trends in the field. The study has been featured as one of the year’s major achievements internationally in clinical cancer research … Read More

February 2, 2017

Advanced GIST Study closing

The impending closure of the Advanced GIST Study, a randomised phase III international study of imatinib in metastatic or locally advanced gastrointestinal stromal tumours (GIST), reflects a critical milestone in the management of this disease.  The AGITG was fortunate to be involved at the outset in this important study, which … Read More

December 7, 2016


INTEGRATE II, an AGITG led Phase III clinical trial in gastro-oesophageal cancer has opened to recruitment.  Support for the final INTEGRATE II trial design was received from Bayer in November 2015.  INTEGRATE II is a Randomised Phase III Double-Blind Placebo-Controlled Study of regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC) which … Read More

December 7, 2016

4th Preceptorship in Colorectal Cancer

The 2016 AGITG Preceptorship in Colorectal Cancer was held on  Friday 11th and Saturday 12th November 2016 in Melbourne. 36 Senior trainees and Junior consultants attended a two day intensive learning course based on a complete review of literature to understand evolution of treatment for colorectal cancer in the adjuvant and metastatic … Read More

December 6, 2016